CD19 and lymphoma: An aptamer-drug complex could selectively deliver doxorubicin into CD19-positve lymphoma cells in vitro, and reduce the drug intake by CD-19 control cells (Figures 7–9), indicating that the aptamer may potentially serve as a tumor-homing ligand for targeted therapy against lymphocytic malignancies.